Dr Kerstin Meyer | Principal Staff Scientist

Meyer, Kerstin

Kerstin Meyer is a principal staff scientist in cellular genetics, working with the Teichmann group and leading Human Cell Atlas projects within the Sanger Institute. Kerstin is using her expertise in molecular biology and transcriptional regulation of gene expression to lead extended pilot studies for data generation for the Human Cell Atlas.

I started my career in immunology, obtaining my PhD from the MRC Laboratory of Molecular Biology, University of Cambridge, where I studied the regulation of immunoglobulin gene expression. I continued to work in this field for a number of years before moving to the CRUK Cambridge Institute investigating genetic risk for breast and lung cancer. I worked in close collaboration with clinicians and computational biologists, using transcriptional networks to understand the combined effect of inherited risk variants for cancer. I am fascinated by the way gene regulatory networks determine cell types and cell states and hope that the Human Cell Atlas will further our understanding in how cell fate decisions are made and can potentially be modified in therapeutic applications. I enjoy working in multidisciplinary teams, bringing together expertise from biology, medicine, computing and technology development to tackle big problems in modern biomedicine, which the Human Cell Atlas has the potential to address.

Publications

  • From Tissues to Cell Types and Back: Single Cell Gene Expression Analysis of Tissue Architecture

    Chen X, Teichmann SA and Meyer KB

    Annual Review Biomedical Data Science 2018

  • ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.

    Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ and Meyer KB

    Cancer research 2018;78;2;410-421

  • Regulators of genetic risk of breast cancer identified by integrative network analysis.

    Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE et al.

    Nature genetics 2016;48;1;12-21

  • Master regulators of FGFR2 signalling and breast cancer risk.

    Fletcher MN, Castro MA, Wang X, de Santiago I, O'Reilly M et al.

    Nature communications 2013;4;2464

  • Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

    Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF et al.

    PLoS biology 2008;6;5;e108

  • Genome-wide association study identifies novel breast cancer susceptibility loci.

    Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al.

    Nature 2007;447;7148;1087-93

  • The immunoglobulin kappa locus contains a second, stronger B-cell-specific enhancer which is located downstream of the constant region.

    Meyer KB and Neuberger MS

    The EMBO journal 1989;8;7;1959-64

  • ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.

    Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ and Meyer KB

    Cancer research 2018;78;2;410-421

  • From Tissues to Cell Types and Back: Single Cell Gene Expression Analysis of Tissue Architecture

    Chen X, Teichmann SA and Meyer KB

    Annual Review Biomedical Data Science 2018

  • Genome-wide CRISPR screens in T helper cells reveal pervasive cross-talk between activation and differentiation

    Henriksson, J, Chen, X, Gomes et al.

    bioRxiv 2018;196022

  • BaalChIP: Bayesian analysis of allele-specific transcription factor binding in cancer genomes.

    de Santiago I, Liu W, Yuan K, O'Reilly M, Chilamakuri CS et al.

    Genome biology 2017;18;1;39

  • FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness.

    Campbell TM, Castro MAA, de Santiago I, Fletcher MNC, Halim S et al.

    Carcinogenesis 2016;37;8;741-750

  • Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

    French JD, Johnatty SE, Lu Y, Beesley J, Gao B et al.

    Oncotarget 2016;7;6;6353-68

  • Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy.

    Campbell TM, Castro MA, Ponder BA and Meyer KB

    PloS one 2016;11;12;e0168770

  • Regulators of genetic risk of breast cancer identified by integrative network analysis.

    Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE et al.

    Nature genetics 2016;48;1;12-21

  • Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.

    Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB et al.

    American journal of human genetics 2015;96;1;5-20

  • FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.

    Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G et al.

    British journal of cancer 2014;110;4;1088-100

  • Fine scale mapping and functional analysis of the breast cancer 11q13 (CCND1) locus

    Meyer, KB, French, JD, Ghoussaini et al.

    Am. J. of Hum. Genetics 2013;92:489-503

  • Master regulators of FGFR2 signalling and breast cancer risk.

    Fletcher MN, Castro MA, Wang X, de Santiago I, O'Reilly M et al.

    Nature communications 2013;4;2464

  • FOXA1 and breast cancer risk.

    Meyer KB and Carroll JS

    Nature genetics 2012;44;11;1176-7

  • RedeR: R/Bioconductor package for representing modular structures, nested networks and multiple levels of hierarchical associations.

    Castro MA, Wang X, Fletcher MN, Meyer KB and Markowetz F

    Genome biology 2012;13;4;R29

  • A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression.

    Meyer KB, Maia AT, O'Reilly M, Ghoussaini M, Prathalingam R et al.

    PLoS genetics 2011;7;7;e1002165

  • Fine scale mapping of the breast cancer 16q12 locus.

    Udler MS, Ahmed S, Healey CS, Meyer K, Struewing J et al.

    Human molecular genetics 2010;19;12;2507-15

  • FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.

    Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP et al.

    Human molecular genetics 2009;18;9;1692-703

  • Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

    Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF et al.

    PLoS biology 2008;6;5;e108

  • Genome-wide association study identifies novel breast cancer susceptibility loci.

    Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al.

    Nature 2007;447;7148;1087-93

  • The chicken Ig light chain 3'-enhancer is essential for gene expression and regulates gene conversion via the transcription factor E2A.

    Conlon TM and Meyer KB

    European journal of immunology 2006;36;1;139-48

  • Gene conversion at the chicken immunoglobulin L genes

    Meyer, KB

    Mod. Asp. of Immunobiol 2006;19, 31

  • Cloning and functional characterisation of avian transcription factor E2A.

    Conlon TM and Meyer KB

    BMC immunology 2004;5;11

Meyer, Kerstin
Kerstin's Timeline
2018

Became Principal Staff Scientist within the Cellular Genetics Group at the Sanger Institute

2017

Joined the Teichmann group as Senior Staff Scientist

2015

Group Leader Department of Oncology, University of Cambridge

2006

Associate Scientist in Prof. Sir Bruce Ponder's laboratory at the CRUK Cambridge Institute and Department of Oncology

1998

Principal investigator and Royal Society University Research Fellow at the CIMR and Department of Pathology, University of Cambridge

1992

Wellcome Trust Career Development Fellow at the Gurdon Institute, University of Cambridge

1990

Completion of PhD at MRC Laboratory of Molecular Biology and start of post-doctoral fellowship